Drug Landscape ›
TELOTRISTAT ETHYL ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 3,056
Most-reported reactions
Diarrhoea — 497 reports (16.26%) Nausea — 422 reports (13.81%) Constipation — 361 reports (11.81%) Abdominal Pain — 358 reports (11.71%) Fatigue — 265 reports (8.67%) Off Label Use — 253 reports (8.28%) Flatulence — 245 reports (8.02%) Headache — 222 reports (7.26%) Drug Ineffective — 220 reports (7.2%) Flushing — 213 reports (6.97%)
Source database →
TELOTRISTAT ETHYL in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is TELOTRISTAT ETHYL approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for TELOTRISTAT ETHYL in United States?
Marketing authorisation holder not available in our data.